Scinai Immunotherapeutics Reports Q1 Revenue of $0.77M, Net Loss of $4.13M, and Raises Additional $4.2M in July-August 2025

Scinai Immunotherapeutics reported 1H revenue of $0.77M, with a net loss of $4.13M, compared to $4.48M in 2024. Cash and cash equivalents totaled $989K as of June 30, 2025, but the company raised an additional $4.2M in July and August 2025 through a Standby Equity Purchase Agreement.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has released its financial results for the first half of 2025, highlighting a significant increase in revenue and a reduction in net loss compared to the same period in 2024. The company reported 1H 2025 revenue of $0.77 million, a substantial rise from $0.284 million in 2024. The net loss for the period was $4.134 million, down from $4.481 million in 2024, primarily driven by higher revenues and lower research and development (R&D) expenses [2].

The company's cash position has been bolstered by a successful fundraising effort. As of June 30, 2025, Scinai's cash and cash equivalents totaled $989,000. Subsequently, in July and August 2025, the company raised an additional $4.2 million through its Standby Equity Purchase Agreement with Yorkville Advisors, significantly strengthening its financial position [1].

Scinai's CDMO business unit, Scinai Bioservices, continues to show growth, contributing $421,000 in revenues in the first half of 2025. The total CDMO service orders for 2025 reached $1.0 million, with invoiced revenues of $850,000 as of August 31, 2025 [2].

The company's R&D activities are focused on advancing its anti-IL-17 NanoAb program, with two product profiles in development. Scinai is also pursuing multiple grant applications, including the EU STEP program and the FENG program, to fund further research and development [2].

Scinai's ability to secure additional capital and the success of its R&D activities remain key uncertainties. The company's future performance will be influenced by factors such as the outcome of its grant applications, the success of its clinical trials, and its ability to expand its CDMO business [2].

References:
[1] https://seekingalpha.com/news/4491144-scinai-immunotherapeutics-reports-1h-results
[2] https://www.prnewswire.com/news-releases/scinai-reports-six-month-2025-financial-results-highlighting-continued-cdmo-revenue-growth-and-strengthened-balance-sheet-302543710.html